Alterations in the Noxa/Mcl-1 Axis Determine Sensitivity of Small Cell Lung Cancer to the BH3 Mimetic ABT-737
Overview
Affiliations
To understand the molecular basis for variable sensitivity to the BH3 mimetic drug ABT-737, the abundance of Bcl-2 family members was assayed in a panel of small cell lung cancer cell lines whose sensitivity varied over a 2-log range. Elevated Noxa and Bcl-2 levels directly correlated with sensitivity to ABT-737, whereas Mcl-1 levels were similar in all cell lines tested regardless of sensitivity. Transgenically enforced expression of Noxa but not Bcl-2 resulted in increased sensitivity to ABT-737 in multiple cell lines. This increase was especially pronounced in the H209 cell line in which expression of Noxa resulted in a proportionate decline in Mcl-1 expression. Although overexpression of Noxa enhanced sensitivity of the H526 and H82 cell lines to ABT-737, it did not result in altered Mcl-1 levels. Similarly, small interfering RNA-mediated knockdown of Noxa expression in the H146 cell line, which increased resistance to ABT-737, did not result in altered Mcl-1 levels. Therefore, three of four cell lines studied failed to show Noxa-mediated regulation of Mcl-1 expression. However, despite failure to regulate Mcl-1 levels, Noxa blocked binding of Bim to Mcl-1 following its release from Bcl-2 by ABT-737. Finally, we observed that a 24-hour incubation of the H526 and WBA cell lines with ABT-737 resulted in increased Noxa expression, suggesting that Noxa may play a direct role in ABT-737-mediated apoptosis. These results indicate that Noxa expression is the critical determinant of ABT-737 sensitivity and loss of Noxa-mediated regulation of Mcl-1 expression may be an important feature of small cell lung cancer biology.
Alam M, Alam S, Shamsi A, Adnan M, Elasbali A, Abu Al-Soud W Front Oncol. 2022; 12:869672.
PMID: 35402265 PMC: 8990771. DOI: 10.3389/fonc.2022.869672.
BH3-mimetics: recent developments in cancer therapy.
Townsend P, Kozhevnikova M, Cexus O, Zamyatnin Jr A, Soond S J Exp Clin Cancer Res. 2021; 40(1):355.
PMID: 34753495 PMC: 8576916. DOI: 10.1186/s13046-021-02157-5.
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.
Innao V, Rizzo V, Allegra A, Musolino C, Allegra A Cells. 2021; 10(2).
PMID: 33669515 PMC: 7922387. DOI: 10.3390/cells10020439.
Florent R, Weiswald L, Lambert B, Brotin E, Abeilard E, Louis M Cell Death Dis. 2020; 11(5):380.
PMID: 32424251 PMC: 7235085. DOI: 10.1038/s41419-020-2588-8.
Song M, Zhang F, Lin L Exp Ther Med. 2019; 18(2):1107-1114.
PMID: 31316606 PMC: 6601140. DOI: 10.3892/etm.2019.7681.